RenovoRx Affirms FY2026 Sales Guidance of $3.000M-$4.000M vs $3.244M Est.

Benzinga Newsdesk www.benzinga.com Negative 62.8%

Neg 62.8% Neu 0% Pos 0%

RenovoRx (NASDAQ:RNXT) affirms FY2026 sales outlook from $3.000 million-$4.000 million to $3.000 million-$4.000 million vs $3.244 million estimate.